Laurus Labs to invest Rs 83 crore in KRKA Pharma

Written by Ruchika Sharma Published On 2025-03-07T16:30:06+05:30 | Updated On 7 March 2025 4:30 PM IST

Laurus Labs to invest Rs 83 crore in KRKA Pharma

Hyderabad: Laurus Labs has announced that the Company has approved an investment of Rs 83 crore in KRKA Pharma, a joint venture of the Company.

"We would like to inform you that the Board of Directors of the Company at their Meeting held on Thursday, 06th March, 2025, inter-alia, have approved for investment of an amount of INR 833,000,000/- (Indian Rupees Eight Hundred and Thirty Three Million only) in KRKA Pharma Private Limited, a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 867,000,000/- in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited.

KRKA Pharma is already a joint venture company of the Company and further investment by the Company and by KRKA d.d., Novo mesto, Slovenia (“co-venturer”) will enable KRKA to acquire land and to meet initial cost of setting up of a manufacturing facility.

The investment by the Company is expected to be completed on or before 31.03.2025.

"The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company’s strategic growth plans and long-term business objectives," the Company stated in a BSE filing.

KRKA Pharma Private Limited, a joint venture of the Company, incorporated under the Companies Act, 2013. The Authorised Share Capital of KRKA is Rs 2700,000,000/- divided into 270,000,000 equity shares of Rs 10/- each and paid-up Share Capital of the Company is Rs 450,000,000/- divided into 45,000,000 equity shares of Rs 10/- each.

Read also: Laurus Bio secures equity infusion of Rs 120 crore

laurus labslaurus labs newsinvestmentKRKA Pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751